Coronary Calcium Score vs. Computed Tomography Angiography as Tools to Stratify Cardiovascular Risk

被引：0
作者：
Bittencourt M.S. [1 ,2 ]
机构：
[1] Preventive Medicine Center Hospital Israelita Albert Einstein & School of Medicine, Faculdade Israelita de Ciência da Saúde Albert Einstein, São Paulo
[2] Center for Clinical and Epidemiological Research, University Hospital and São Paulo State Cancer Institute, University of São Paulo, AV. Lineu Prestes, 2565, Butantã, São Paulo
来源：
Current Cardiovascular Risk Reports | 2018年 / 12卷 / 8期
关键词：
Atherosclerosis; Cardiovascular risk; Coronary artery calcium score; Coronary computed tomography angiography; Primary prevention;
D O I：
10.1007/s12170-018-0584-7
中图分类号：
学科分类号：
摘要：
Purpose of Review: This review evaluates the evidence for and against the use of coronary artery calcium (CAC) score and coronary computed tomography angiography (CTA) on the cardiovascular risk stratification for primary prevention in asymptomatic individuals. Recent Findings: Recent evidence suggests that the presence and extent of CAC are robust predictors of events across various populations and variable baseline risk. On the other hand, the absence of CAC is associated with a good prognosis event in older individuals or in those with multiple risk factor or high clinical risk. While coronary CTA is also useful for risk stratification, its results did not provide incremental discrimination of individuals once the CAC is accounted for. Thus, current evidence does not support its use in asymptomatic individuals. Summary: CAC is a powerful tool for additional cardiovascular risk stratification in individuals where the need for pharmacological therapy for risk reduction in primary prevention is uncertain, such as in individuals with intermediate risk. Since coronary CTA does not further improve risk stratification in this population, it is not currently recommended in asymptomatic individuals. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 36 条
  • [1] Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corra U., Cosyns B., Deaton C., Graham I., Hall M.S., Richard Hobbs F.D., Lochen M.L., Lollgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y., Tiberi M., Bart van der Worp H., van Dis I., Monique Verschuren W.M., 2016 European Guidelines on cardiovascular disease prevention in clinical practice, Rev Esp Cardiol (Engl Ed), 69, 10, (2016)
  • [2] Goff, Lloyd-Jones D.M., Bennett G., Coadyd'agostino S., Gibbons R., Et al., ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J am Coll Cardiol, 63, 25, pp. 2935-2959, (2013)
  • [3] Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., Reiner Z., Riccardi G., Taskinen M.R., Tokgozoglu L., Verschuren W.M., Vlachopoulos C., Wood D.A., Zamorano J.L., 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the Euro
  • [4] Whelton P.K., Carey R.M., Aronowcasey W.S., Collins K.J., Himmelfarb C.D., Et al., ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines, J am Coll Cardiol, 71, 19, pp. e127-e248, (2018)
  • [5] Mora S., Ames J.M., Manson J.E., Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice, JAMA, 316, 7, pp. 709-710, (2016)
  • [6] DeFilippis A.P., Young R., Carrubba C.J., Et al., An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort, Ann Intern Med, 162, 4, pp. 266-275, (2015)
  • [7] Andersson C., Enserro D., Larson M.G., Xanthakis V., Vasan R.S., Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort, J Am Heart Assoc, 4, 4, (2015)
  • [8] Muntner P., Colantonio L.D., Cushman M., Goff D.C., Howard G., Howard V.J., Kissela B., Levitan E.B., Lloyd-Jones D.M., Safford M.M., Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations, JAMA, 311, 14, pp. 1406-1415, (2014)
  • [9] Defilippis A.P., Young R., McEvoy J.W., Michos E.D., Sandfort V., Kronmal R.A., Et al., Risk score overestimation: The impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort, Eur Heart J, 38, 8, pp. 598-608, (2017)
  • [10] Margolis J.R., Chen J.T., Kong Y., Peter R.H., Behar V.S., Kisslo J.A., The diagnostic and prognostic significance of coronary artery calcification. A report of 800 cases, Radiology, 137, 3, pp. 609-616, (1980)
1234